Even emerging migraine treatments such as cannabinoids (Leimuranta et al., 2018) directly inhibited P2X2 and P2X2/3 receptors in sensory neurons (Krishtal et al., 2006) which can provide a dual anti-nociceptive effect. This evidence concerns the gene P2RX2 and migraine disorder.